BioSpecifics Technologies Corp. (BSTC)

[surf1944]

6:29AM BioSpecifics Tech. confirms FDA approval of XIAFLEX for treatment of Dupuytren's contracture (BSTC) 27.00 : Co confirms the FDA has approved XIAFLEX, a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord. Dupuytren's contracture is a debilitating disease resulting from excessive collagen deposition that causes contractures of the fingers.